Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen™, is a plasmid (supercoiled circular DNA) encoding
gene p62/SQSTM1. Elenagen™ reverses tumor grade, changes tumor microenvironment,
enhances the anti-cancer effects of other therapies (e.g. chemotherapy),
mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen™.
The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
Based on these successful results, we initiated Phase II Clinical Trials outside of the
United States
, and are now preparing Phase II Clinical Trials within the US.
 

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen™, is a plasmid (supercoiled circular DNA) encoding
gene p62/SQSTM1. Elenagen™ reverses tumor grade, changes tumor microenvironment,
enhances the anti-cancer effects of other therapies (e.g. chemotherapy),
mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen™.
The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
Based on these successful results, we initiated Phase II Clinical Trials outside of the
United States
, and are now preparing Phase II Clinical Trials within the US.
Elegan is a plasmid (Circular DNA) Encoding Gene P62/SQSTM1

Clinical Trials


The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen™. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.

Elegan is a plasmid (Circular DNA) Encoding Gene P62/SQSTM1

Completed phase I/IIa clinical trial



Elenagen™: Case Study

Elenagen™: Case Study



International Clinical Trials 2019

International Clinical Trials 2019



US clinical trials

US clinical trials



Elegan is a plasmid (Circular DNA) Encoding Gene P62/SQSTM1

Completed phase I/IIa clinical trial



Elenagen™: Case Study

Elenagen™: Case Study



International Clinical Trials 2019

International Clinical Trials 2019



US clinical trials

US clinical trials



Alexander Shneider

Alexander Shneider, Ph.D.


Founder and CEO



Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle, advisor at We Fund Health. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Vlad Gabai, Ph.D.

Vlad
Gabai,
Ph.D.


VP of R&D



Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
Mr. Charles Legg

Mr.
Charles
Legg


COO



Over 20 years of successful biotech and big pharma experience ranging from program & portfolio manager at the international pharmaceutical company, Shire Pharmaceuticals, to the first full-time employee of the gene therapy startup, Solid Ventures. Successful projects in molecular diagnostics, drug discovery from early POC to pivotal clinical trials, from commercial launching to global expansion, from early seed funding to two $100MM+ IPOs. Focus on gene therapy and immuno-oncology.
Ilya Lapshin-1

Ilya Lapshin,
JD


General Council



18 years of legal experience in a large New York law firm and two Massachusetts-based boutique firms helping startups and big corporate clients. Between a double major at MIT, Physics with Electrical Engineering and Math, and Boston University Law School, successful entrepreneurial and startup experience including a lucrative exit from a business, which Ilya started as a co-founder as soon as he came to the US.
Franco Venanzi

Franco Venanzi,
Ph.D.


Director of Basic Research



Over 30 years of biomedical research, over 20 years of tenured faculty professorship at University of Camerino, Italy, where was Head of the Translational Biology Laboratory, 20 years of service as editor-in-chief, editorial board member and a reviewer for vaccination and immunobiology journals.
Hong Lee, MD, MBA, MPH, MS

Hong Lee, MD, MBA, MPH, MS


Interim Clinical Director



Over 20 years extensive global clinical development and medical affairs strategic experience, outstanding proven track records in US, Europe, and Asian-pacific. As a clinical/medical/project lead, led global cross function teams to develop clinical and/or medical plans, conduct international trials across multiple therapeutic indications and cross phases 1-4 and postmarketing, to meet scientific, regulatory and commercial needs, with high quality and in a timely/on budget/scientifically responsible fashion.
Vita Shcherbinina

Mss.
Vita Shcherbinina


Regional Manager



10 years of management experience in international biotech R&D projects from pre-clinical proof of concept to multicenter clinical trials. Previously, 5 years of company assessment and asset valuation experience in banking industry.

SCIENTIFIC ADVISORY BOARD

Aaron Ciechanover
– Nobel Prize in Chemistry 2004, Technion, Haifa, Director of Cancer Control Center, Israel
Kim Lewis
– Distinguished Professor of Biology, Director of Antimicrobial Drug Discovery Center, Northeastern University
Michael Sherman
– Professor of Biochemistry, Boston University School of Medicine
Stuart Calderwood
– Associate Professor, Scientific Director of Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
Adolfo García-Sastre
– Mount Sinai Hospital, Icahn school of Medicine; Professor of Microbiology, Professor of Medicine and Infectious Diseases, Director, Global Health and Emerging Pathogens Institute, Director, Center for Research on Influenza Pathogenesis
Roland Baron, DDS, PhD
– Professor of Oral Medicine, Infection, and Immunity and Chair of the Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, U.S.
Dr. Marvin Gilmore, Jr.
– Board member for Mount Auburn Hospital, UMass Boston, New England Conservatory of Music, New Market Business Association; Trustee for Boston Local Development Corporation (BLDC)
Givi Topchishvili
–   Serial entrepreneur, investor, inventor, author with 30 years of successful business track record across numerous sectors.
Prof. Sergei Krasny, MD, PhD
- Deputy Director for Research, N.N. Alexandrov National Cancer Center, Minsk, Belarus

Contact us: info@curelab.com